Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway

Background and Aims Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatoc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology (Baltimore, Md.) Md.), 2021-08, Vol.74 (2), p.686-703
Hauptverfasser: Lan, Tian, Yu, Yang, Zhang, Jing, Li, Haonan, Weng, Qiqing, Jiang, Shuo, Tian, Song, Xu, Tonghao, Hu, Sha, Yang, Guizhi, Zhang, Yan, Wang, Weixuan, Wang, Lexun, Zhu, Qing, Rong, Xianglu, Guo, Jiao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 703
container_issue 2
container_start_page 686
container_title Hepatology (Baltimore, Md.)
container_volume 74
creator Lan, Tian
Yu, Yang
Zhang, Jing
Li, Haonan
Weng, Qiqing
Jiang, Shuo
Tian, Song
Xu, Tonghao
Hu, Sha
Yang, Guizhi
Zhang, Yan
Wang, Weixuan
Wang, Lexun
Zhu, Qing
Rong, Xianglu
Guo, Jiao
description Background and Aims Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases. Approach and Results We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH. Conclusion Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH.
doi_str_mv 10.1002/hep.31749
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8457150</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2564444003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4439-c78a83767d30c6cadacd5c55668ae36093a5297b61efffd078dc850ed2de548d3</originalsourceid><addsrcrecordid>eNp1kc1uEzEURi0EomlhwQsgS2xgMa3HP2PPBimKCkUUiFRYW459J-NqMg6202p2fQSekSfBkFABEt5Y9j0699ofQs9qcloTQs962J6yWvL2AZrVgsqKMUEeohmhklRtzdojdJzSNSGk5VQ9RkelLhvCxAxNixDdZGHrRzzfwOBDNBkS_hhGM9jQh8FbfJXB5FC6mOyzT3g14bnN_qYcw4hDh3MPeP5h-f3u2-EeHF7GkKFY3_vRJMBXfl2Mflzjpcn9rZmeoEedGRI8Pewn6Mub88-Li-ry09t3i_llZTlnbWWlMorJRjpGbGONM9YJK0TTKAOsIS0zgrZy1dTQdZ0jUjmrBAFHHQiuHDtBr_fe7W61AWdhzNEMehv9xsRJB-P135XR93odbrTiQtaCFMHLgyCGrztIWW98sjAMZoSwS5py1VLBBaMFffEPeh12sby7UKLhZRHCCvVqT9kYUorQ3Q9TE_0zUF2-Wv8KtLDP_5z-nvydYAHO9sCtH2D6v0lfnC_3yh95RK3q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564444003</pqid></control><display><type>article</type><title>Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lan, Tian ; Yu, Yang ; Zhang, Jing ; Li, Haonan ; Weng, Qiqing ; Jiang, Shuo ; Tian, Song ; Xu, Tonghao ; Hu, Sha ; Yang, Guizhi ; Zhang, Yan ; Wang, Weixuan ; Wang, Lexun ; Zhu, Qing ; Rong, Xianglu ; Guo, Jiao</creator><creatorcontrib>Lan, Tian ; Yu, Yang ; Zhang, Jing ; Li, Haonan ; Weng, Qiqing ; Jiang, Shuo ; Tian, Song ; Xu, Tonghao ; Hu, Sha ; Yang, Guizhi ; Zhang, Yan ; Wang, Weixuan ; Wang, Lexun ; Zhu, Qing ; Rong, Xianglu ; Guo, Jiao</creatorcontrib><description>Background and Aims Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases. Approach and Results We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH. Conclusion Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH.</description><identifier>ISSN: 0270-9139</identifier><identifier>ISSN: 1527-3350</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.31749</identifier><identifier>PMID: 33576035</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc</publisher><subject>AMP-Activated Protein Kinases - metabolism ; Animals ; Cell Line ; Cordycepin ; Deoxyadenosines - pharmacology ; Deoxyadenosines - therapeutic use ; Fatty liver ; Fibrosis ; Hepatocytes ; Hepatology ; Humans ; Inflammation ; Kinases ; Liver ; Liver - drug effects ; Liver - immunology ; Liver - pathology ; Liver Cirrhosis - immunology ; Liver Cirrhosis - pathology ; Liver Cirrhosis - prevention &amp; control ; Liver diseases ; Liver transplantation ; Metabolic disorders ; Metabolic rate ; Metabolic syndrome ; Mice ; Natural products ; Non-alcoholic Fatty Liver Disease - drug therapy ; Non-alcoholic Fatty Liver Disease - immunology ; Non-alcoholic Fatty Liver Disease - pathology ; Original ; Phosphorylation ; Protein kinase ; Signal transduction ; Signal Transduction - drug effects ; Signal Transduction - immunology ; Steatosis ; Traditional Chinese medicine</subject><ispartof>Hepatology (Baltimore, Md.), 2021-08, Vol.74 (2), p.686-703</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.</rights><rights>2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4439-c78a83767d30c6cadacd5c55668ae36093a5297b61efffd078dc850ed2de548d3</citedby><cites>FETCH-LOGICAL-c4439-c78a83767d30c6cadacd5c55668ae36093a5297b61efffd078dc850ed2de548d3</cites><orcidid>0000-0002-5783-6883</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.31749$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.31749$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33576035$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lan, Tian</creatorcontrib><creatorcontrib>Yu, Yang</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Li, Haonan</creatorcontrib><creatorcontrib>Weng, Qiqing</creatorcontrib><creatorcontrib>Jiang, Shuo</creatorcontrib><creatorcontrib>Tian, Song</creatorcontrib><creatorcontrib>Xu, Tonghao</creatorcontrib><creatorcontrib>Hu, Sha</creatorcontrib><creatorcontrib>Yang, Guizhi</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Wang, Weixuan</creatorcontrib><creatorcontrib>Wang, Lexun</creatorcontrib><creatorcontrib>Zhu, Qing</creatorcontrib><creatorcontrib>Rong, Xianglu</creatorcontrib><creatorcontrib>Guo, Jiao</creatorcontrib><title>Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>Background and Aims Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases. Approach and Results We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH. Conclusion Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH.</description><subject>AMP-Activated Protein Kinases - metabolism</subject><subject>Animals</subject><subject>Cell Line</subject><subject>Cordycepin</subject><subject>Deoxyadenosines - pharmacology</subject><subject>Deoxyadenosines - therapeutic use</subject><subject>Fatty liver</subject><subject>Fibrosis</subject><subject>Hepatocytes</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Kinases</subject><subject>Liver</subject><subject>Liver - drug effects</subject><subject>Liver - immunology</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - immunology</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver Cirrhosis - prevention &amp; control</subject><subject>Liver diseases</subject><subject>Liver transplantation</subject><subject>Metabolic disorders</subject><subject>Metabolic rate</subject><subject>Metabolic syndrome</subject><subject>Mice</subject><subject>Natural products</subject><subject>Non-alcoholic Fatty Liver Disease - drug therapy</subject><subject>Non-alcoholic Fatty Liver Disease - immunology</subject><subject>Non-alcoholic Fatty Liver Disease - pathology</subject><subject>Original</subject><subject>Phosphorylation</subject><subject>Protein kinase</subject><subject>Signal transduction</subject><subject>Signal Transduction - drug effects</subject><subject>Signal Transduction - immunology</subject><subject>Steatosis</subject><subject>Traditional Chinese medicine</subject><issn>0270-9139</issn><issn>1527-3350</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1uEzEURi0EomlhwQsgS2xgMa3HP2PPBimKCkUUiFRYW459J-NqMg6202p2fQSekSfBkFABEt5Y9j0699ofQs9qcloTQs962J6yWvL2AZrVgsqKMUEeohmhklRtzdojdJzSNSGk5VQ9RkelLhvCxAxNixDdZGHrRzzfwOBDNBkS_hhGM9jQh8FbfJXB5FC6mOyzT3g14bnN_qYcw4hDh3MPeP5h-f3u2-EeHF7GkKFY3_vRJMBXfl2Mflzjpcn9rZmeoEedGRI8Pewn6Mub88-Li-ry09t3i_llZTlnbWWlMorJRjpGbGONM9YJK0TTKAOsIS0zgrZy1dTQdZ0jUjmrBAFHHQiuHDtBr_fe7W61AWdhzNEMehv9xsRJB-P135XR93odbrTiQtaCFMHLgyCGrztIWW98sjAMZoSwS5py1VLBBaMFffEPeh12sby7UKLhZRHCCvVqT9kYUorQ3Q9TE_0zUF2-Wv8KtLDP_5z-nvydYAHO9sCtH2D6v0lfnC_3yh95RK3q</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Lan, Tian</creator><creator>Yu, Yang</creator><creator>Zhang, Jing</creator><creator>Li, Haonan</creator><creator>Weng, Qiqing</creator><creator>Jiang, Shuo</creator><creator>Tian, Song</creator><creator>Xu, Tonghao</creator><creator>Hu, Sha</creator><creator>Yang, Guizhi</creator><creator>Zhang, Yan</creator><creator>Wang, Weixuan</creator><creator>Wang, Lexun</creator><creator>Zhu, Qing</creator><creator>Rong, Xianglu</creator><creator>Guo, Jiao</creator><general>Wolters Kluwer Health, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5783-6883</orcidid></search><sort><creationdate>202108</creationdate><title>Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway</title><author>Lan, Tian ; Yu, Yang ; Zhang, Jing ; Li, Haonan ; Weng, Qiqing ; Jiang, Shuo ; Tian, Song ; Xu, Tonghao ; Hu, Sha ; Yang, Guizhi ; Zhang, Yan ; Wang, Weixuan ; Wang, Lexun ; Zhu, Qing ; Rong, Xianglu ; Guo, Jiao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4439-c78a83767d30c6cadacd5c55668ae36093a5297b61efffd078dc850ed2de548d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>AMP-Activated Protein Kinases - metabolism</topic><topic>Animals</topic><topic>Cell Line</topic><topic>Cordycepin</topic><topic>Deoxyadenosines - pharmacology</topic><topic>Deoxyadenosines - therapeutic use</topic><topic>Fatty liver</topic><topic>Fibrosis</topic><topic>Hepatocytes</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Kinases</topic><topic>Liver</topic><topic>Liver - drug effects</topic><topic>Liver - immunology</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - immunology</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver Cirrhosis - prevention &amp; control</topic><topic>Liver diseases</topic><topic>Liver transplantation</topic><topic>Metabolic disorders</topic><topic>Metabolic rate</topic><topic>Metabolic syndrome</topic><topic>Mice</topic><topic>Natural products</topic><topic>Non-alcoholic Fatty Liver Disease - drug therapy</topic><topic>Non-alcoholic Fatty Liver Disease - immunology</topic><topic>Non-alcoholic Fatty Liver Disease - pathology</topic><topic>Original</topic><topic>Phosphorylation</topic><topic>Protein kinase</topic><topic>Signal transduction</topic><topic>Signal Transduction - drug effects</topic><topic>Signal Transduction - immunology</topic><topic>Steatosis</topic><topic>Traditional Chinese medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lan, Tian</creatorcontrib><creatorcontrib>Yu, Yang</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Li, Haonan</creatorcontrib><creatorcontrib>Weng, Qiqing</creatorcontrib><creatorcontrib>Jiang, Shuo</creatorcontrib><creatorcontrib>Tian, Song</creatorcontrib><creatorcontrib>Xu, Tonghao</creatorcontrib><creatorcontrib>Hu, Sha</creatorcontrib><creatorcontrib>Yang, Guizhi</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Wang, Weixuan</creatorcontrib><creatorcontrib>Wang, Lexun</creatorcontrib><creatorcontrib>Zhu, Qing</creatorcontrib><creatorcontrib>Rong, Xianglu</creatorcontrib><creatorcontrib>Guo, Jiao</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lan, Tian</au><au>Yu, Yang</au><au>Zhang, Jing</au><au>Li, Haonan</au><au>Weng, Qiqing</au><au>Jiang, Shuo</au><au>Tian, Song</au><au>Xu, Tonghao</au><au>Hu, Sha</au><au>Yang, Guizhi</au><au>Zhang, Yan</au><au>Wang, Weixuan</au><au>Wang, Lexun</au><au>Zhu, Qing</au><au>Rong, Xianglu</au><au>Guo, Jiao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2021-08</date><risdate>2021</risdate><volume>74</volume><issue>2</issue><spage>686</spage><epage>703</epage><pages>686-703</pages><issn>0270-9139</issn><issn>1527-3350</issn><eissn>1527-3350</eissn><abstract>Background and Aims Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases. Approach and Results We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH. Conclusion Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH.</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>33576035</pmid><doi>10.1002/hep.31749</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-5783-6883</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0270-9139
ispartof Hepatology (Baltimore, Md.), 2021-08, Vol.74 (2), p.686-703
issn 0270-9139
1527-3350
1527-3350
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8457150
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects AMP-Activated Protein Kinases - metabolism
Animals
Cell Line
Cordycepin
Deoxyadenosines - pharmacology
Deoxyadenosines - therapeutic use
Fatty liver
Fibrosis
Hepatocytes
Hepatology
Humans
Inflammation
Kinases
Liver
Liver - drug effects
Liver - immunology
Liver - pathology
Liver Cirrhosis - immunology
Liver Cirrhosis - pathology
Liver Cirrhosis - prevention & control
Liver diseases
Liver transplantation
Metabolic disorders
Metabolic rate
Metabolic syndrome
Mice
Natural products
Non-alcoholic Fatty Liver Disease - drug therapy
Non-alcoholic Fatty Liver Disease - immunology
Non-alcoholic Fatty Liver Disease - pathology
Original
Phosphorylation
Protein kinase
Signal transduction
Signal Transduction - drug effects
Signal Transduction - immunology
Steatosis
Traditional Chinese medicine
title Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T00%3A24%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cordycepin%20Ameliorates%20Nonalcoholic%20Steatohepatitis%20by%20Activation%20of%20the%20AMP%E2%80%90Activated%20Protein%20Kinase%20Signaling%20Pathway&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Lan,%20Tian&rft.date=2021-08&rft.volume=74&rft.issue=2&rft.spage=686&rft.epage=703&rft.pages=686-703&rft.issn=0270-9139&rft.eissn=1527-3350&rft_id=info:doi/10.1002/hep.31749&rft_dat=%3Cproquest_pubme%3E2564444003%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2564444003&rft_id=info:pmid/33576035&rfr_iscdi=true